Which medication has growing evidence as an effective adjunctive therapy for NAS, though further prospective trials are warranted?

• A. Clonidine
• B. Buprenorphine
• C. Diazepam
• D. Phenobarbital

Answer: (A)

Adjunctive therapy for neonatal abstinence syndrome targets the autonomic withdrawal symptoms to lessen overall opioid exposure and treatment duration. Clonidine, an alpha-2 adrenergic agonist, dampens sympathetic outflow, which helps reduce tachycardia, hypertension, sweating, irritability, and agitation that accompany NAS. By tempering these autonomic signs, clonidine can decrease the amount of opioid replacement needed (morphine or methadone) and may shorten hospital stay, making it a helpful adjunct to primary opioid therapy. This approach is supported by growing clinical evidence, though larger prospective trials are still needed to solidify optimal dosing and safety profiles.

It's important to monitor for potential hypotension and bradycardia, especially when used with other sedatives or opioids. Other agents like diazepam or phenobarbital can add sedation and carry CNS depression risks without effectively addressing the autonomic symptoms of NAS, and while buprenorphine can be used as a primary opioid therapy, clonidine stands out as a well-supported adjunctive option in the evolving evidence base.